A little more than a week after the Senate parliamentarian doused what little hope there was for drug pricing legislation this year, FDA approved a treatment for Alzheimer’s that many warn could be costly to Medicare, though the cost to taxpayers of aducanumab will depend on whether Medicare restricts coverage. The Senate parliamentarian’s recent ruling stops Democrats from recycling a third time the 2021 budget resolution and reconciliation instructions that was used for the American Rescue Plan, several sources say...